ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,843,820 | +4.9% | 425,500 | 0.0% | 1.07% | +18.2% |
| Q2 2023 | $37,975,875 | -16.8% | 425,500 | 0.0% | 0.90% | -17.1% |
| Q1 2023 | $45,622,110 | -12.2% | 425,500 | 0.0% | 1.09% | -12.9% |
| Q4 2022 | $51,966,315 | +18.3% | 425,500 | 0.0% | 1.25% | +10.1% |
| Q3 2022 | $43,937,000 | +11.1% | 425,500 | 0.0% | 1.14% | -1.4% |
| Q2 2022 | $39,554,000 | -19.3% | 425,500 | +1.9% | 1.15% | -6.7% |
| Q1 2022 | $48,998,000 | -8.9% | 417,500 | +4.4% | 1.23% | -0.8% |
| Q4 2021 | $53,812,000 | -15.6% | 400,000 | 0.0% | 1.24% | -7.3% |
| Q3 2021 | $63,756,000 | +107.6% | 400,000 | +71.3% | 1.34% | +120.9% |
| Q2 2021 | $30,717,000 | +2.1% | 233,500 | 0.0% | 0.61% | -7.6% |
| Q1 2021 | $30,093,000 | -22.7% | 233,500 | 0.0% | 0.66% | -20.5% |
| Q4 2020 | $38,943,000 | +8.1% | 233,500 | 0.0% | 0.83% | -9.6% |
| Q3 2020 | $36,034,000 | +14.1% | 233,500 | +9.4% | 0.91% | +5.5% |
| Q2 2020 | $31,577,000 | +31.3% | 213,500 | 0.0% | 0.87% | -12.9% |
| Q1 2020 | $24,042,000 | -19.1% | 213,500 | 0.0% | 0.99% | +6.0% |
| Q4 2019 | $29,702,000 | +44.4% | 213,500 | 0.0% | 0.94% | +14.5% |
| Q3 2019 | $20,564,000 | -16.4% | 213,500 | 0.0% | 0.82% | -7.9% |
| Q2 2019 | $24,585,000 | -2.2% | 213,500 | 0.0% | 0.89% | -8.3% |
| Q1 2019 | $25,129,000 | +64.7% | 213,500 | -12.3% | 0.97% | +34.6% |
| Q4 2018 | $15,255,000 | -11.6% | 243,500 | 0.0% | 0.72% | +15.2% |
| Q3 2018 | $17,254,000 | +6.5% | 243,500 | 0.0% | 0.62% | +0.3% |
| Q2 2018 | $16,198,000 | -12.6% | 243,500 | -14.1% | 0.62% | -21.2% |
| Q1 2018 | $18,541,000 | +65.3% | 283,500 | +1.2% | 0.79% | +55.4% |
| Q4 2017 | $11,217,000 | +10.5% | 280,000 | 0.0% | 0.51% | +8.8% |
| Q3 2017 | $10,150,000 | +12.5% | 280,000 | -13.8% | 0.47% | +2.6% |
| Q2 2017 | $9,022,000 | -0.9% | 325,000 | 0.0% | 0.46% | -13.1% |
| Q1 2017 | $9,100,000 | +38.3% | 325,000 | 0.0% | 0.52% | +19.3% |
| Q4 2016 | $6,578,000 | +9.1% | 325,000 | +8.3% | 0.44% | +16.4% |
| Q3 2016 | $6,030,000 | +51.5% | 300,000 | 0.0% | 0.38% | +28.1% |
| Q2 2016 | $3,981,000 | -20.5% | 300,000 | +11.1% | 0.30% | -29.8% |
| Q1 2016 | $5,009,000 | +1.3% | 270,000 | 0.0% | 0.42% | +12.0% |
| Q4 2015 | $4,946,000 | +3.5% | 270,000 | 0.0% | 0.38% | -3.4% |
| Q3 2015 | $4,779,000 | +12.6% | 270,000 | +12.5% | 0.39% | +25.2% |
| Q2 2015 | $4,243,000 | +587.7% | 240,000 | +575.3% | 0.31% | +434.5% |
| Q1 2015 | $617,000 | – | 35,540 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |